NOVONIX Ltd Files 6-K Report for October 2024

Ticker: NVNXF · Form: 6-K · Filed: Oct 3, 2024 · CIK: 1859795

Sentiment: neutral

Topics: sec-filing, 6-K, disclosure

TL;DR

NOVONIX dropped a 6-K for Oct 2024, check Appendix 3H for deets.

AI Summary

NOVONIX Limited filed a Form 6-K on October 3, 2024, reporting for the month of October 2024. The filing includes Appendix 3H, which is a notification regarding the company's activities. NOVONIX is incorporated in Australia and its principal executive office is located in Brisbane.

Why It Matters

This filing provides an update on NOVONIX's corporate activities and disclosures as a foreign private issuer, which is important for investors tracking the company's ongoing operations and compliance.

Risk Assessment

Risk Level: low — This is a routine filing (6-K) that primarily serves as a notification and does not appear to contain significant new financial or operational disclosures that would immediately alter risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the registrant may be required to disclose to any security holders.

What specific exhibit is mentioned in this 6-K filing?

Exhibit 99.1, titled 'Appendix 3H (Notificat', is mentioned in the filing.

What is NOVONIX Limited's fiscal year end?

NOVONIX Limited's fiscal year ends on December 31.

Where is NOVONIX Limited's principal executive office located?

NOVONIX Limited's principal executive office is located at Level 38, 71 Eagle Street, Brisbane, QLD 4000, Australia.

Does NOVONIX Limited file its annual reports under Form 20-F or Form 40-F?

NOVONIX Limited indicates that it files its annual reports under cover of Form 20-F.

Filing Stats: 210 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-10-02 18:33:16

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVONIX LIMITED By: /s/ Dr. John Christopher Burns Dr. John Christopher Burns Chief Executive Officer Date: October 2, 2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing